TRT Gel denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for trt gel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Issues a "Not FDA-Approved" Denial for Testosterone Gel

A "not FDA-approved" denial on a testosterone gel claim is unusual, because topical testosterone gels do hold FDA approval for specific indications. This type of denial typically signals one of three situations: (1) UHC believes the prescribed use falls outside the FDA-approved indication for that product, (2) the specific brand or compounded formulation prescribed does not carry its own FDA approval, or (3) there is a coding or documentation mismatch that led the system to treat the claim as an unapproved use. Each has a distinct appeal path.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): File within 180 days of the denial notice. UHC must decide within 30 days for standard reviews, 72 hours for expedited.
• External review: If the internal appeal fails, escalate to an independent review organization (IRO) within approximately four months of final internal denial. The IRO's decision binds the plan.
• Expedited track: Available when delay poses a serious health risk.

## Identify the Exact Basis of the Denial

Before drafting your appeal, obtain the denial letter's specific language and the applicable UHC coverage policy. The appeal strategy differs by root cause:

• If the indication is FDA-approved: Provide a copy of the FDA-approved prescribing label highlighting the approved indication. Request that UHC identify precisely which aspect of the use it considers off-label, and rebut with the label text.
• If the product is compounded: Compounded testosterone is not FDA-approved as a finished drug product. Your prescriber must explain why a compounded formulation is medically necessary over an FDA-approved commercial product, per applicable guidelines from the Endocrine Society and FDA compounding guidance.
• If it is a documentation/coding issue: Provide corrected diagnosis codes, the prescriber's confirmation of the approved indication, and a letter of medical necessity.

## What to Gather

1. FDA prescribing label — printed current label for the specific product, with indication section clearly marked. 2. Prescribing physician's letter — confirms the prescribed use aligns with the FDA-approved indication and explains the clinical basis. 3. Diagnosis documentation — lab-confirmed hypogonadism consistent with the labeled indication. 4. Applicable guideline reference — the prescriber should cite the Endocrine Society guideline to support that the use is standard of care. 5. Denial policy reference — obtain UHC's specific coverage policy number and respond to each stated criterion.

## Criteria-Mapping Structure

| Denial Basis Stated by UHC | Your Rebuttal Evidence | |---|---| | Use is off-label | FDA label — indication section (attached) | | Product not FDA-approved | FDA approval documentation or compounding rationale | | Documentation gap | Corrected codes, prescriber confirmation letter |